文献速递白血病造血干细胞移植与细胞治疗

供者来源CD19靶向T细胞输注可使异基因造血干细胞移植后复发且对供者淋巴细胞输注无反应的B细胞急性淋巴细胞白血病获得微小残留病阴性缓解

Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2017-10-26

研究纳入2015年1月至2017年1月间异基因造血干细胞移植后复发且对供者淋巴细胞输注无反应的B细胞急性淋巴细胞白血病患者,接受供者来源CD19靶向CAR T细胞输注。5例(83.33%)达到微小残留病阴性缓解,但5例缓解者中4例在2-7个月后复发。5例(83.33%)发生1-3级细胞因子释放综合征,2例发生2级、1例发生3级急性移植物抗宿主病。

要点

  • 供者来源CD19 CAR T细胞可使部分移植后复发B-ALL患者达MRD阴性缓解。
  • 5例(83.33%)达MRD阴性缓解,但5例缓解者中4例在2-7个月后复发。
  • 5例(83.33%)发生1-3级细胞因子释放综合征,2例使用托珠单抗治疗。

核心结论

  • 供者来源CAR T细胞输注对异基因造血干细胞移植后复发的B-ALL似乎有效且安全,但需要更大规模的临床研究。

研究设计与样本

  • 2015年1月至2017年1月间,2例和4例患者分别接受1次和2次来自异基因造血干细胞移植供者的CAR T细胞输注。

主要发现

  • 5例(83.33%)达到微小残留病阴性缓解;1例在发生严重血栓性微血管病后未评估即自动出院。
  • 5例缓解者中4例在2-7个月后复发,1例在第二次输注后达MRD阴性缓解后死于脓毒症。
  • 其他接受第二次输注的患者均未达到第二次完全缓解。
  • 5例(83.33%)发生8次1-3级细胞因子释放综合征,其中2例接受托珠单抗治疗。
  • 2例(33.3%)和1例分别发生2级和3级急性移植物抗宿主病,前者经糖皮质激素控制。

局限性

  • 需要更大规模的临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is a common cause of failure in patients with B-cell acute lymphoblastic leukaemia (B-ALL) after haploidentical haematopoietic stem cell transplantation (haplo-HSCT), and non-responders to donor lymphoblastic infusion after HSCT have a very poor prognosis. Although donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B-ALL cases after haplo-HSCT. Between January 2015 and January 2017, two and four patients each received one and two infusions of CAR T cells from haplo-HSCT donors. Five (83·33%) achieved minimal residual disease (MRD)-negative remission; one patient was discharged automatically without evaluation after developing severe thrombotic microangiopathies. Four of five responsive patients relapsed after 2-7 months, and one died of sepsis following MRD-negative remission after a second infusion. None of the other second infusion recipients achieved a second complete remission. Five patients (83·33%) experienced eight courses of grade 1-3 cytokine release syndrome; two were treated with tocilizumab. Two (33·3%) and one patient developed grade 2 and 3 acute graft-versus-host disease (aGVHD), respectively; the former was controlled with glucocorticoids. Donor-derived CAR T-cell infusion seems be effective and safe for relapsed B-ALL after haplo-HSCT, although larger clinical studies are needed.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017. PMID: 29076142. doi:10.1111/bjh.14923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。